β-Thalassemia · governance
PDPA & consent notice
Research preview · all data shown in this demonstrator are synthetic. Any future use on real patient data requires Thailand PDPA-compliant consent and IRB approval.
What this build uses
- Synthetic patient cohort generated for demonstration only.
- No personally identifiable information (PII) and no protected health information (PHI).
- No data leaves the browser; the predictions are computed client-side.
What real-data use will require
- Thailand PDPA (Personal Data Protection Act B.E. 2562 / 2019) lawful basis, documented in a data-protection impact assessment.
- Written patient consent for the specific decision-support use and for any audit-log capture.
- IRB / institutional ethics approval covering both silent-mode and prospective evaluation.
- Data-processing agreement with the model provider and explicit data-residency choice.
- Re-identification risk review of any exported decision-capture artefact.
Synthetic-data acknowledgement
This records a local acknowledgement (browser localStorage) that you are exploring synthetic demonstrator content. It is not a substitute for PDPA consent or IRB approval, which are required before any real-patient-data use.
This interface presents outputs of a research-preview prediction model. It is not a regulated decision-support tool. Predictions come from one calibrated XGBoost classifier per endpoint, fitted on a synthetic-labeled cohort (no PHI; labels anchored to published base rates) and evaluated on a held-out synthetic test split. Not pre-registered; not externally validated.